Format

Send to

Choose Destination
Trends Mol Med. 2009 Mar;15(3):112-9. doi: 10.1016/j.molmed.2009.01.003. Epub 2009 Feb 24.

Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.

Author information

1
MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, De Crespigny Park, London, SE5 8AF, UK. Diane.Hanger@kcl.ac.uk

Abstract

The microtubule-associated protein tau is integral to the pathogenesis of Alzheimer's disease (AD), as well as several related disorders, termed tauopathies, in which tau is deposited in affected brain regions. In the tauopathies, pathological tau is in an elevated state of phosphorylation and is aberrantly cleaved. It also exhibits abnormal conformations and becomes aggregated, resulting in neurofibrillary tau pathology. Recent evidence suggests that relatively early disease-associated changes in soluble tau proteins, including phosphorylation, are involved in the induction of neuronal death. Here, we summarize recent developments that suggest new therapeutic strategies to prevent or reduce the progression of pathology in the tauopathies. A list of tau phosphorylation sites identified in the tauopathies and in controls accompanies this review.

PMID:
19246243
DOI:
10.1016/j.molmed.2009.01.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center